Page 2221 - Williams Hematology ( PDFDrive )

2196 Part XII: Hemostasis and Thrombosis Chapter 128: Hemostatic Alterations in Liver Disease and Liver Transplantation 2197

20. Hugenholtz GG, Porte RJ, Lisman T: The platelet and platelet function testing in liver 52. Munoz SJ, Rajender Reddy K, Lee W; Acute Liver Failure Study Group: The coagu-
disease. Clin Liver Dis 13(1):11–20, 2009. lopathy of acute liver failure and implications for intracranial pressure monitoring.
21. Kerr R, Newsome P, Germain L, et al: Effects of acute liver injury on blood coagulation. Neurocrit Care 9(1):103–107, 2008.
J Thromb Haemost 1(4):754–759, 2003. 53. Lisman T, Bakhtiari K, Adelmeijer J, et al: Intact thrombin generation and decreased
22. Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR: A conditional knockout mouse fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb
model reveals endothelial cells as the principal and possibly exclusive source of plasma Haemost 10(7):1312–1319, 2012.
factor VIII. Blood 123(24):3706–3713, 2014. 54. Stravitz RT, Lisman T, Luketic VA, et al: Minimal effects of acute liver injury/acute liver
23. Blanchard RA, Furie BC, Jorgensen M, et al: Acquired vitamin K-dependent carboxyla- failure on hemostasis as assessed by thromboelastography. J Hepatol 56(1):129–136, 2012.
tion deficiency in liver disease. N Engl J Med 305(5):242–248, 1981. 55. Hugenholtz GC, Adelmeijer J, Meijers JC, et al: An unbalance between von Willebrand
24. Tripodi A, Mannucci PM: The coagulopathy of chronic liver disease. N Engl J Med factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical
365(2):147–156, 2011. outcome. Hepatology 58(2):752–761, 2013.
25. de Maat MP, Nieuwenhuizen W, Knot EA, et al: Measuring plasma fibrinogen levels in 56. Pernambuco JR, Langley PG, Hughes RD, et al: Activation of the fibrinolytic system in
patients with liver cirrhosis. The occurrence of proteolytic fibrin(ogen) degradation prod- patients with fulminant liver failure. Hepatology 18(6):1350–1356, 1993.
ucts and their influence on several fibrinogen assays. Thromb Res 78(4):353–362, 1995. 57. Stravitz RT, Bowling R, Bradford RL, et al: Role of procoagulant microparticles in medi-
26. Francis JL, Armstrong DJ: Acquired dysfibrinogenaemia in liver disease. J Clin Pathol ating complications and outcome of acute liver injury/acute liver failure. Hepatology
35(6):667–672, 1982. 58(1):304–313, 2013.
27. Tripodi A, Salerno F, Chantarangkul V, et al: Evidence of normal thrombin genera- 58. Munoz SJ, Stravitz RT, Gabriel DA: Coagulopathy of acute liver failure. Clin Liver Dis
tion in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 41(3): 13(1):95–107, 2009.
553–558, 2005. 59. Porte RJ, Knot EA, Bontempo FA: Hemostasis in liver transplantation. Gastroenterology
28. Lisman T, Bakhtiari K, Pereboom IT, et al: Normal to increased thrombin generation in 97(2):488–501, 1989.
patients undergoing liver transplantation despite prolonged conventional coagulation 59a. Bakker CM, Blankensteijn JD, Schlejen P, et al: The effects of long-term graft preser-
tests. J Hepatol 52(3):355–361, 2010. vation on intraoperative hemostatic changes in liver transplantation. A comparison
29. Gatt A, Riddell A, Calvaruso V, et al: Enhanced thrombin generation in patients with between orthotopic and heterotopic transplantation in the pig. HPB Surg 7(4):265–80,
cirrhosis-induced coagulopathy. J Thromb Haemost 8(9):1994–2000, 2010. 1994.
30. Potze W, Arshad F, Adelmeijer J, et al: Differential in vitro inhibition of thrombin 59b. de Boer MT, Westerkamp A, van den Berg AP, et al: Impact of extended criteria donor
generation by anticoagulant drugs in plasma from patients with cirrhosis. PloS One grafts on post-reperfusion transfusion requirements in liver transplantation; abstract
9(2):e88390, 2014. Liver Transpl 15(7):S128–S129, 2009.
31. Lisman T, Porte RJ: Rebalanced hemostasis in patients with liver disease: Evidence and 60. de Boer MT, Molenaar IQ, Hendriks HG, et al: Minimizing blood loss in liver trans-
clinical consequences. Blood 116(6):878–885, 2010. plantation: Progress through research and evolution of techniques. Dig Surg 22(4):
32. Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory methodologies achieve 265–275, 2005.
higher model for endstage liver disease (MELD) scores for patients listed for liver trans- 61. Massicotte L, Denault AY, Beaulieu D, et al: Transfusion rate for 500 consecutive
plantation. Liver Transpl 10(8):995–1000, 2004. liver transplantations: Experience of one liver transplantation center. Transplantation
33. Lisman T, van Leeuwen Y, Adelmeijer J, et al: Interlaboratory variability in assessment 93(12):1276–1281, 2012.
of the model of end-stage liver disease score. Liver Int 28(10):1344–1351, 2008. 62. Kang YG, Martin DJ, Marquez J, et al: Intraoperative changes in blood coagulation and
34. Tripodi A, Chantarangkul V, Primignani M, et al: The international normalized ratio thrombelastographic monitoring in liver transplantation. Anesth Analg 64(9):888–896,
calibrated for cirrhosis (INR[liver]) normalizes prothrombin time results for model for 1985.
end-stage liver disease calculation. Hepatology 46(2):520–527, 2007. 63. Porte RJ, Bontempo FA, Knot EA, et al: Systemic effects of tissue plasminogen
35. Bellest L, Eschwege V, Poupon R, et al: A modified international normalized ratio activator-associated fibrinolysis and its relation to thrombin generation in orthotopic
as an effective way of prothrombin time standardization in hepatology. Hepatology liver transplantation. Transplantation 47(6):978–984, 1989.
46(2):528–534, 2007. 64. Sindram D, Porte RJ, Hoffman MR, et al: Platelets induce sinusoidal endothelial cell
36. Leebeek FW: Hyperfibrinolysis in Liver Disease. CRC Press, Boca Raton, FL, 1996. apoptosis upon reperfusion of the cold ischemic rat liver. Gastroenterology 118(1):
37. Leebeek FW, Kluft C, Knot EA, et al: A shift in balance between profibrinolytic and 183–191, 2000.
antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 65. Agarwal S, Senzolo M, Melikian C, et al: The prevalence of a heparin-like effect shown
101(5):1382–1390, 1991. on the thromboelastograph in patients undergoing liver transplantation. Liver Transpl
38. Lisman T, Leebeek FW, Mosnier LO, et al: Thrombin-activatable fibrinolysis inhib- 14(6):855–860, 2008.
itor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. 66. Pereboom IT, Adelmeijer J, van Leeuwen Y, et al: Development of a severe von
Gastroenterology 121(1):131–139, 2001. Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am
39. Stravitz RT: Potential applications of thromboelastography in patients with acute and J Transplant 9(5):1189–1196, 2009.
chronic liver disease. Nat Rev Gastroenterol Hepatol 8(8):513–520, 2012. 67. Stahl RL, Duncan A, Hooks MA, et al: A hypercoagulable state follows orthotopic liver
40. Rijken DC, Kock EL, Guimaraes AH, et al: Evidence for an enhanced fibrinolytic transplantation. Hepatology 12(3 Pt 1):553–558, 1990.
capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb 68. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH: Hemostasis and fibrinolysis in severe
Haemost 10(10):2116–2122, 2012. liver failure and their relation to hemorrhage. Hepatology 6(1):79–86, 1986.
41. Violi F, Ferro D, Basili S, et al: Association between low-grade disseminated intravas- 69. Garcia-Tsao G, Bosch J: Management of varices and variceal hemorrhage in cirrhosis.
cular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology N Engl J Med 362(9):823–832, 2010.
109(2):531–539, 1995. 70. Villanueva C, Colomo A, Bosch A, et al: Transfusion strategies for acute upper gastro-
42. Francis RB Jr, Feinstein DI: Clinical significance of accelerated fibrinolysis in liver dis- intestinal bleeding. N Engl J Med 368(1):11–21, 2013.
ease. Haemostasis 14(6):460–465, 1984. 71. Castaneda B, Debernardi-Venon W, Bandi JC, et al: The role of portal pressure in the
43. Violi F, Ferro D, Basili S, et al: Hyperfibrinolysis increases the risk of gastrointestinal severity of bleeding in portal hypertensive rats. Hepatology 31(3):581–586, 2000.
hemorrhage in patients with advanced cirrhosis. Hepatology 15(4):672–676, 1992. 72. Marti-Carvajal AJ, Karakitsiou DE, Salanti G: Human recombinant activated factor VII
44. Tripodi A, Anstee QM, Sogaard KK, et al: Hypercoagulability in cirrhosis: Causes and for upper gastrointestinal bleeding in patients with liver diseases. Cochrane Database
consequences. J Thromb Haemost 9(9):1713–1723, 2011. Syst Rev 3:CD004887, 2012.
45. Lisman T, Caldwell SH, Leebeek FW, Porte RJ: Is chronic liver disease associated with a 73. Holster IL, Poley JW, Kuipers EJ, Tjwa ET: Controlling gastric variceal bleeding with
bleeding diathesis? J Thromb Haemost 4(9):2059–2060, 2006. endoscopically applied hemostatic powder (Hemospray). J Hepatol 57(6):1397–1398,
46. Massicotte L, Lenis S, Thibeault L, et al: Effect of low central venous pressure and phle- 2012.
botomy on blood product transfusion requirements during liver transplantations. Liver 74. Sung JJ, Luo D, Wu JC, et al: Early clinical experience of the safety and effectiveness
Transpl 12(1):117–123, 2006. of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding.
47. De Gottardi A, Thevenot T, Spahr L, et al: Risk of complications after abdominal para- Endoscopy 43(4):291–295, 2011.
centesis in cirrhotic patients: A prospective study. Clin Gastroenterol Hepatol 7(8): 75. De Gottardi A, Thevenot T, Spahr L, et al: Risk of complications after abdominal para-
906–909, 2009. centesis in cirrhotic patients: A prospective study. Clin Gastroenterol Hepatol 7(8):
48. Sogaard KK, Horvath-Puho E, Gronbaek H, et al: Risk of venous thromboembolism 906–909, 2009.
in patients with liver disease: A nationwide population-based case-control study. Am J 76. Piccinino F, Sagnelli E, Pasquale G, Giusti G: Complications following percutaneous
Gastroenterol 104(1):96–101, 2009. liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 2(2):
49. Northup PG, McMahon MM, Ruhl AP, et al: Coagulopathy does not fully protect 165–173, 1986.
hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J 77. Segal JB, Dzik WH, Transfusion Medicine/Hemostasis Clinical Trials Network: Paucity
Gastroenterol 101(7):1524–1528; quiz 1680, 2006. of studies to support that abnormal coagulation test results predict bleeding in the set-
50. Gulley D, Teal E, Suvannasankha A, et al: Deep vein thrombosis and pulmonary embo- ting of invasive procedures: An evidence-based review. Transfusion 45(9):1413–1425,
lism in cirrhosis patients. Dig Dis Sci 53(11):3012–3017, 2008. 2005.
51. Vivas S, Rodriguez M, Palacio MA, et al: Presence of bacterial infection in bleeding 78. Youssef WI, Salazar F, Dasarathy S, et al: Role of fresh frozen plasma infusion in cor-
cirrhotic patients is independently associated with early mortality and failure to control rection of coagulopathy of chronic liver disease: A dual phase study. Am J Gastroenterol
bleeding. Dig Dis Sci 46(12):2752–2757, 2001. 98(6):1391–1394, 2003.

Kaushansky_chapter 128_p2191-2198.indd 2196 9/18/15 10:38 AM